Botanix Pharmaceuticals Passes FDA mid-cycle review for Sofpironium Bromide
Botanix Pharmaceuticals’ (BOT) lead product, Sofpironium Bromide, passes an FDA mid-cycle review
The FDA detected...
Botanix Pharmaceuticals has released its September quarterly report, showing the company ended the period with a strong $22.1M in the bank
That's enough...
